Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H, Laurie J, Austin M, Gallipoli P, Taylor T, Dennis M, Elliot J, Clarke G, Dang R, Vidler J, Krishnamurthy P, Latif AL, Kalkur P, Shahidianakbar M, Campbell V, Mannari D, Sutherland E, Wickramaratne T, Collins A, Zhao R, Mak H, Belsham E, Banerjee S, Bashir J, Pillai S, Whitmill R, Galli S, Amer M, Murthy V, Murray D, Wandroo F, Hogan F, Crolla F, Fowler N, Khan A, O'Nions J, Dillon R

Open source

DOI: 10.1016/j.bneo.2024.100017
Published: 2024 Sep
Container: Blood neoplasia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.bneo.2024.100017,
  title = {Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.},
  author = {Othman J and Lam HPJ and Leong S and Basheer F and Abdallah I and Fleming K and Mehta P and Yassin H and Laurie J and Austin M and Gallipoli P and Taylor T and Dennis M and Elliot J and Clarke G and Dang R and Vidler J and Krishnamurthy P and Latif AL and Kalkur P and Shahidianakbar M and Campbell V and Mannari D and Sutherland E and Wickramaratne T and Collins A and Zhao R and Mak H and Belsham E and Banerjee S and Bashir J and Pillai S and Whitmill R and Galli S and Amer M and Murthy V and Murray D and Wandroo F and Hogan F and Crolla F and Fowler N and Khan A and O'Nions J and Dillon R},
  year = {2024},
  journal = {Blood neoplasia},
  doi = {10.1016/j.bneo.2024.100017},
  url = {https://doi.org/10.1016/j.bneo.2024.100017}
}

RIS

TY  - JOUR
TI  - Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.
AU  - Othman J
AU  - Lam HPJ
AU  - Leong S
AU  - Basheer F
AU  - Abdallah I
AU  - Fleming K
AU  - Mehta P
AU  - Yassin H
AU  - Laurie J
AU  - Austin M
AU  - Gallipoli P
AU  - Taylor T
AU  - Dennis M
AU  - Elliot J
AU  - Clarke G
AU  - Dang R
AU  - Vidler J
AU  - Krishnamurthy P
AU  - Latif AL
AU  - Kalkur P
AU  - Shahidianakbar M
AU  - Campbell V
AU  - Mannari D
AU  - Sutherland E
AU  - Wickramaratne T
AU  - Collins A
AU  - Zhao R
AU  - Mak H
AU  - Belsham E
AU  - Banerjee S
AU  - Bashir J
AU  - Pillai S
AU  - Whitmill R
AU  - Galli S
AU  - Amer M
AU  - Murthy V
AU  - Murray D
AU  - Wandroo F
AU  - Hogan F
AU  - Crolla F
AU  - Fowler N
AU  - Khan A
AU  - O'Nions J
AU  - Dillon R
PY  - 2024
JO  - Blood neoplasia
DO  - 10.1016/j.bneo.2024.100017
UR  - https://doi.org/10.1016/j.bneo.2024.100017
ER  -

APA

J, O., HPJ, L., S, L., F, B., I, A., K, F., P, M., H, Y., J, L., M, A., P, G., T, T., M, D., J, E., G, C., R, D., J, V., P, K., AL, L., P, K., M, S., V, C., D, M., E, S., T, W., A, C., R, Z., H, M., E, B., S, B., J, B., S, P., R, W., S, G., M, A., V, M., D, M., F, W., F, H., F, C., N, F., A, K., J, O., & R, D. (2024). Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2024.100017

Source records

pubmed · retrieved 2026-09-25T23:59:59.851Z